Clearmind Medicine enrolls first Alcohol Use Disorder patients in CMND-100 clinical trial
CMND is trading near its 52-week low of $0.92 (3.1% above the low) on light trading volume (0.4× avg).
Summary
Clearmind Medicine announced the enrollment of the first patients with Alcohol Use Disorder (AUD) in its CMND-100 clinical trial, a major step forward in evaluating the psychedelic-based treatment candidate.
Key Events · Product Development and Regulatory · CMND
-
First AUD Patients Enrolled
Clearmind Medicine has enrolled the first two patients with Alcohol Use Disorder (AUD) in its CMND-100 clinical trial at Hadassah Medical Center in Jerusalem, Israel.
-
Advancement in Clinical Program
This marks the first time CMND-100 is being administered to patients with AUD, following previous evaluations in healthy participants. The trial will assess safety, tolerability, pharmacokinetics, and preliminary efficacy.
Analysis · CMND · Life Sciences
This marks a significant advancement for Clearmind Medicine's CMND-100 program, as it transitions from testing in healthy volunteers to administering the treatment to actual patients with Alcohol Use Disorder (AUD). For a clinical-stage biopharmaceutical company, enrolling the first patients in the target population is a critical de-risking step, validating the drug's potential and moving the program closer to key clinical milestones. This progress is particularly important for a micro-cap company, as successful clinical development is essential for future value creation.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 37.3% of the 989 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.86%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CMND was trading at $0.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.3M. The 52-week trading range was $0.92 to $524.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.